drugset / Trial / NCT02271009

Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC

NCT02271009

Phase 2 Completed 213 enrolled Anergis Inflamax Research Incorporated · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to find the optimal dose of AllerT that should be used to treat moderate to severe allergies due to birch tree pollen. There are 4 treatment groups in this study; 3 treatment groups will receive AllerT at different doses and 1 treatment group will receive placebo. This study will also assess the effectiveness and safety of AllerT compared to placebo in relieving allergy symptoms.

Timeline

Start
2014-10
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator AllerT Peptide 10 ug Subcutaneous
Comparator AllerT Peptide 25 ug Subcutaneous
Comparator AllerT Peptide 50 ug Subcutaneous

Indications